{"product_id":"moffitt-cancer-center-19th-annual-clinical-breakthroughs","title":"Moffitt Cancer Center 19th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2024","description":"\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"Grid__row___Zwj70 Grid__small___cFccF\"\u003e\n\u003cdiv class=\"Grid__column___sR0HF Grid__col_12___Na7lf Grid__small___cFccF\"\u003e\n\u003cdiv class=\"App__widgetIdcontainer___ms2gn\" id=\"widget:4ffd7cc7-cb7b-4f03-a26a-1c2bea98c9f2\"\u003e\n\u003cdiv class=\"Text__container___l2Chv\" data-cvent-id=\"widget-NucleusText-widget:4ffd7cc7-cb7b-4f03-a26a-1c2bea98c9f2\"\u003e\n\u003cdiv class=\"css-vsf5of\"\u003e\n\u003cp class=\"carina-rte-public-DraftStyleDefault-block\"\u003eMoffitt Cancer Center 19th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2024 This conference is designed specifically for hematologists, medical oncologists, pharmacists, pharmacy techs, fellows, advanced practice professionals, oncology nurses and other healthcare professionals who are interested in this field.\u003c\/p\u003e\n\u003cbr\u003e \u003cbr\u003e\u003col\u003e\n\u003cli class=\"carina-rte-public-DraftStyleDefault-block\"\u003eHear the latest updates from leading experts in the field including updates from the latest ASH meeting in December 2023.\u003c\/li\u003e\n\u003cli class=\"carina-rte-public-DraftStyleDefault-block\"\u003eEngage with colleagues in a world class resort and relaxed atmosphere.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003ch4\u003e14 videos + 1 pdf, size: 3.78 GB\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cstrong\u003eLEARNING OBJECTIVES\u003c\/strong\u003e\n\u003cbr\u003e\u003cul class=\"carina-rte-public-DraftStyleDefault-ul\"\u003e\n\u003cli\u003eDiscuss treatment options available for high risk MDS patients\u003c\/li\u003e\n\u003cli\u003eExamine new immune based therapies, including CAR T-cell therapy, in the treatment of multiple myeloma\u003c\/li\u003e\n\u003cli\u003eDescribe therapeutic and molecular strategies for managing patients with Non-Hodgkin’s lymphoma\u003c\/li\u003e\n\u003cli\u003eExamine the management of older adult patients with AML\u003c\/li\u003e\n\u003cli\u003eRecognize some of the newer issues affecting the care of Hematology patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eTARGET AUDIENCE\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eThis conference is designed specifically for hematologists, medical oncologists, pharmacists, pharmacy techs, fellows, advanced practice professionals, oncology nurses and other healthcare professionals who are interested in this field.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eFINAL.Heme-Conference-AGENDA-2024-v21.pdf\u003c\/li\u003e\n\u003cli\u003eHot Off the Press Lymphoid Diseases.mp4\u003c\/li\u003e\n\u003cli\u003eHot Off the Press Myeloid Diseases.mp4\u003c\/li\u003e\n\u003cli\u003eHot Off the Press Plasma Cell Dyscrasias.mp4\u003c\/li\u003e\n\u003cli\u003eLymphoid Malignancies Debate Harnessing the Immune System to Manage Relapsed Refractory Diffuse Large B Cell Lymphom No.mp4\u003c\/li\u003e\n\u003cli\u003eLymphoid Malignancies Debate Harnessing the Immune System to Manage Relapsed Refractory Diffuse Large B Cell\u003c\/li\u003e\n\u003cli\u003eLymphom Yes.mp4\u003c\/li\u003e\n\u003cli\u003eLymphoid Malignancies Interactive Case Discussion Optimal Management of Patients with CLL.mp4\u003c\/li\u003e\n\u003cli\u003eLymphoid Malignancies State of the Art Frontline Treatment of Advanced Stage Hodgkin Lymphoma.mp4\u003c\/li\u003e\n\u003cli\u003eMultiple Myeloma Debate Response-adapted approach to transplant in newly diagnosed MM are we there yet No.mp4\u003c\/li\u003e\n\u003cli\u003eMultiple Myeloma Debate Response-adapted approach to transplant in newly diagnosed MM are we there yet Yes.mp4\u003c\/li\u003e\n\u003cli\u003eMultiple Myeloma Interactive Case Discussion Optimal timing of CART-cell therapy in myeloma.mp4\u003c\/li\u003e\n\u003cli\u003eMultiple Myeloma State of the Art Bi-specifics antibodies in myeloma Which How When.mp4\u003c\/li\u003e\n\u003cli\u003eMyeloid Malignancies Debate- Worst of the worst- Should we transplant patients with p53 mutant MDS or AML Yes.mp4\u003c\/li\u003e\n\u003cli\u003eMyeloid Malignancies Interactive Case Discussion- Optimal use of targeted therapy for the elderly or unfit AML patient.mp4\u003c\/li\u003e\n\u003cli\u003eMyeloid Malignancies State of the Art- Making Sense of the New Classification Systems for MDS.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003ch3\u003eClinical Breakthroughs and Challenges\u003cbr\u003ein Hematologic Malignancies\u003cbr\u003eJanuary 27, 2024\u003cbr\u003eAGENDA\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e7:00-8:00 am Breakfast and Registration\u003cbr\u003e8:00-8:05 am Welcome and Introductions\u003cbr\u003eSESSION Lymphoid Malignancies — Moderator: Celeste Bello, MD\u003cbr\u003e8:05-8:30 am State of the Art: Frontline Treatment of Advanced Stage Hodgkin Lymphoma\u003cbr\u003eHayder Saeed, MD\u003cbr\u003e8:30-8:55 am Interactive Case Discussion: Optimal Management of Patients with CLL\u003cbr\u003eJavier Pinilla, MD\u003cbr\u003e8:55-9:25 am Debate: Harnessing the Immune System to Manage Relapsed\/Refractory Diffuse Large B Cell Lymphoma: Are\u003cbr\u003eBispecific Antibodies Superior to CAR T Cell Therapy?\u003cbr\u003eYes: Julio Chavez, MD | No: Aleksandr Lazaryan, MD, MPH, PhD\u003cbr\u003e9:25-9:30 am Audience Interaction — Vote Now!\u003cbr\u003e9:30-9:55 am Break and Exhibits\u003cbr\u003eSESSION Myeloid Malignancies — Moderator: Eric Padron, MD\u003cbr\u003e9:55-10:25 am State of the Art: Making Sense of the New Classification Systems for MDS\u003cbr\u003eRami Komrokji, MD\u003cbr\u003e10:25-10:55 am Interactive Case Discussion: Optimal use of targeted therapy for the elderly or unfit AML patient\u003cbr\u003eOnyee Chan, MD\u003cbr\u003e11:00-11:30 am Debate: Worst of the worst: Should we transplant patients with p53 mutant MDS or AML\u003cbr\u003eYes: Hany Elmariah, MD, MS | No: David Sallman, MD\u003cbr\u003e11:25-11:30 am Audience Interaction — Vote Now!\u003cbr\u003e11:30 am-12:45 pm Networking Lunch and Exhibits\u003cbr\u003eSESSION Multiple Myeloma — Moderator: Melissa Alsina, MD\u003cbr\u003e12:45-1:10 pm State of the Art: Bi-specifics antibodies in myeloma: Which? How? When?\u003cbr\u003eAriel Grajales-Cruz, MD\u003cbr\u003e1:10-1:35 pm Interactive Case Discussion: Optimal timing of CART-cell therapy in myeloma\u003cbr\u003eCiara Freeman, MD\u003cbr\u003e1:35-2:05 pm Debate: Response-adapted approach to transplant in newly diagnosed MM: are we there yet?\u003cbr\u003eYes: Ken Shain, MD | No: Omar Castañeda-Puglianini, MD\u003cbr\u003e2:05-2:10 pm Audience Interaction — Vote Now!\u003cbr\u003e2:10-2:35 pm Break and Exhibits\u003cbr\u003e2:35-2:45 pm Raffle Winners Announced (you must be present to win)\u003cbr\u003eSESSION Hot Off the Press! — Moderator: Jeffrey Lancet, MD\u003cbr\u003e2:45-3:15 pm Myeloid Diseases\u003cbr\u003ePresenter: Andrew Kuykendall, MD\u003cbr\u003ePanel: Rami Komrokji, MD; Onyee Chan, MD; David Sallman, MD\u003cbr\u003e3:15-3:45 pm Lymphoid Diseases\u003cbr\u003ePresenter: Bijal Shah, MD\u003cbr\u003ePanel: Hayder Saeed, MD; Julio Chavez, MD; Javier Pinilla, MD; and Aleksandr Lazaryan, MD\u003cbr\u003e3:45-4:15 pm Plasma Cell Dyscrasias\u003cbr\u003ePresenter: Rachid Baz, MD\u003cbr\u003ePanel: Melissa Alsina, MD; Kenneth Shain, MD, PhD; Ariel Grajales-Cruz, MD\u003cbr\u003e4:15-4:30 pm Closing RemarkS\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954370777186,"sku":"MED-AMB02075","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Moffitt-Cancer-Center-19th-Annual-Clinical-Breakthroughs-and-Challenges-in-Hematologic-Malignancies-2024.jpg?v=1779374804","url":"https:\/\/meducourse.com\/products\/moffitt-cancer-center-19th-annual-clinical-breakthroughs","provider":"Meducourse","version":"1.0","type":"link"}